VUTRISIRAN
Information current as at: 1 June 2026
PBAC meeting date: July 2026
Submission Details
- Brand name:
-
- Amvuttra®
- Form and strength:
-
- Injection 25 mg (as sodium) in 0.5 mL pre-filled syringe
- Submission sponsor:
- MEDISON PHARMA AUSTRALIA PTY LIMITED
- Condition/indication:
(therapeutic use) -
- Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Listing requested:
- To request listing of vutrisiran for the treatment of adult patients with wild-type or hereditary ATTR-CM with documented evidence of the transthyretin precursor protein present who have experienced at least one episode of hospitalisation that was a direct result of heart failure or have clinical evidence of heart failure without hospitalisation that required treatment with a diuretic for improvement.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (Written) for initial treatment Authority Required (Telephone/Online) for continuing treatment
- PBAC Submission type:
- Change to existing listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
1246
Page last updated
31 May 2026
v.9.19